Aminoglycosides are a class of antibiotics that kill bacteria by binding to their ribosomes, corrupting the translation of genetic code into proteins. First discovered in the 1940s with streptomycin, the class now includes widely used drugs like gentamicin, tobramycin, and amikacin. Their bactericidal punch comes from a distinctive and somewhat unusual mechanism: rather than simply halting protein production, aminoglycosides cause the ribosome to misread its instructions, flooding the cell with defective proteins that ultimately destroy the bacterial membrane from within.
How Aminoglycosides Target the Ribosome
The primary target is a small stretch of RNA in the bacterial ribosome’s decoding center, specifically a region called the A site on the 16S ribosomal RNA of the 30S subunit. Aminoglycosides like paromomycin, neomycin, and gentamicin bind to highly conserved nucleotides in this region.1PubMed. Structural origins of aminoglycoside specificity for prokaryotic ribosomes When the drug locks into this site, it forces two key nucleotides (A1492 and A1493) into a flipped-out position, mimicking what normally happens only when the correct transfer RNA has been matched to a messenger RNA codon. The ribosome is essentially tricked into accepting the wrong building blocks.2PubMed Central. Roles of specific aminoglycoside-ribosome interactions in the inhibition of translation
A reasonable question is why aminoglycosides damage bacterial ribosomes without wreaking havoc on human ribosomes, since both organisms use ribosomes to make proteins. The answer lies in a single nucleotide difference. At position 1408 in the ribosomal RNA, bacteria have an adenine (A), while eukaryotic cells have a guanine (G). That one-letter change dramatically reduces how tightly aminoglycosides can bind, giving the drugs their selectivity for bacterial targets.1PubMed. Structural origins of aminoglycoside specificity for prokaryotic ribosomes The selectivity is not perfect, though, and that imperfection is the root of aminoglycoside side effects, a topic explored below.
From Misreading to Cell Death
What sets aminoglycosides apart from many other ribosome-targeting antibiotics is that they are bactericidal, meaning they actively kill bacteria rather than just slowing their growth. The misreading of mRNA is the opening move, but what follows is a cascading, self-reinforcing process. Defective proteins produced by drug-corrupted ribosomes get inserted into the bacterial cell membrane, where they form abnormal channels. These channels allow more aminoglycoside molecules to flood into the cell, which causes even more misreading and even more defective membrane proteins.3PubMed Central. Misread protein creates membrane channels: an essential step in the bactericidal action of aminoglycosides The cycle feeds on itself until the membrane is fatally compromised.
There is also an oxidative dimension to this killing. Research in E. coli has shown that mistranslated proteins inserted into the membrane activate envelope stress-response systems, which in turn alter the cell’s metabolism and respiratory pathways. The net result is a buildup of damaging reactive oxygen species, including hydroxyl radicals, that contribute to cell death.4PubMed Central. Mistranslation of membrane proteins and two-component system activation trigger aminoglycoside-mediated oxidative stress and cell death This oxidative component helps explain why aminoglycosides are lethal to bacteria even at concentrations where other ribosome inhibitors merely slow growth.
Getting Inside the Cell
Before any of this can happen, the drug has to reach the ribosome. Aminoglycosides are positively charged molecules, and their entry into gram-negative bacteria involves crossing both an outer membrane studded with negatively charged lipopolysaccharides and an inner cytoplasmic membrane. Despite decades of study, the exact uptake pathway remains incompletely understood.5PubMed Central. Aminoglycoside uptake, stress, and potentiation in Gram-negative bacteria: new therapies with old molecules What is clear is that uptake occurs in phases: a small amount of drug initially crosses the membrane through an energy-dependent process, triggers the first wave of misreading, and the resulting membrane damage then permits a much larger influx. This staged entry is part of why aminoglycosides show concentration-dependent killing, where higher peak concentrations produce faster and more thorough bacterial death.
Resistance Through Enzymatic Modification
The most widespread mechanism of aminoglycoside resistance involves enzymes that chemically modify the drug before it can reach the ribosome. Bacteria produce three broad families of aminoglycoside-modifying enzymes, each adding a different chemical group to the antibiotic molecule:
- Phosphotransferases (APHs): These transfer a phosphate group from ATP onto a hydroxyl group of the aminoglycoside, weakening its ability to bind the ribosomal target.6PubMed Central. Transient kinetics of aminoglycoside phosphotransferase(3′)-IIIa reveals a potential drug target in the antibiotic resistance mechanism Drugs like streptomycin and kanamycin are frequent substrates.7PubMed. The crystal structure of aminoglycoside-3′-phosphotransferase-IIa, an enzyme responsible for antibiotic resistance
- Acetyltransferases (AACs): These attach an acetyl group to an amino group on the drug, again preventing effective ribosome binding.
- Nucleotidyltransferases (ANTs): These add a nucleotide (usually adenine) to a hydroxyl group. A recently identified enzyme, ANT(3″)-Ic from Citrobacter telavivum, inactivates streptomycin and spectinomycin through this mechanism.8PubMed Central. Identification of a novel aminoglycoside nucleotidyltransferase ANT(3″)-Ic from Citrobacter telavivum S24
These enzymes are often encoded on mobile genetic elements like plasmids, which makes them easy to share between bacterial species. Some bacteria even carry bifunctional enzymes capable of performing two types of modification. One example from Serratia marcescens catalyzes both adenylation of streptomycin and acetylation of kanamycin, giving the bacterium a broader resistance profile from a single enzyme.9PubMed. Characterization of the bifunctional aminoglycoside-modifying enzyme ANT(3”)-Ii/AAC(6′)-IId from Serratia marcescens The sheer diversity of these enzymes, covering different aminoglycosides and modification sites, makes enzymatic resistance the single most clinically challenging mechanism to overcome.
Resistance Through Ribosomal Methylation
A more recently recognized and arguably more alarming form of resistance involves methylation of the ribosomal target itself. Bacteria can acquire genes encoding 16S rRNA methyltransferases, enzymes that add a methyl group to the very nucleotides where aminoglycosides bind. This blocks drug binding entirely and confers high-level resistance to essentially all clinically used aminoglycosides, including gentamicin, tobramycin, amikacin, and even the newer agent plazomicin.10PubMed Central. Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases
The origin story of these enzymes is instructive. Aminoglycoside-producing soil bacteria (Actinobacteria) naturally make 16S rRNA methyltransferases to protect themselves from their own antibiotic metabolites. Genes encoding these self-protection enzymes have been transferred to human pathogens. At least ten acquired methyltransferases have been identified in gram-negative pathogens, with two key variants, ArmA and NpmA, modifying positions G1405 and A1408 in the ribosomal A site, respectively.11PubMed Central. Aminoglycoside resistance 16S rRNA methyltransferases block endogenous methylation, affect translation efficiency and fitness of the host Strains carrying these genes are frequently multidrug-resistant or extensively drug-resistant, which severely limits treatment options.10PubMed Central. Aminoglycoside Resistance: The Emergence of Acquired 16S Ribosomal RNA Methyltransferases
Efflux Pumps and Outer Membrane Barriers
Bacteria can also resist aminoglycosides simply by pumping the drug back out or preventing it from getting in. In Pseudomonas aeruginosa, a notorious cause of hospital-acquired infections, the MexXY-OprM efflux pump actively removes aminoglycosides from the cell interior.12PubMed Central. MexXY-OprM efflux pump is required for antagonism of aminoglycosides by divalent cations in Pseudomonas aeruginosa Genome analysis of over 600 clinical P. aeruginosa isolates found that more than half had mutations predicted to increase expression of this efflux system.13PubMed. Aminoglycoside resistance in Pseudomonas aeruginosa: the contribution of the MexXY-OprM efflux pump varies between isolates The contribution of efflux varies between isolates, meaning it can be the primary resistance mechanism in some strains and a minor player in others. Permeability barriers, including changes to outer membrane porins and lipopolysaccharide modifications that reduce the negative surface charge, further decrease the amount of drug that reaches the cytoplasm.
Why Aminoglycosides Pair Well With Beta-Lactams
One of the most clinically useful features of aminoglycosides is their synergy with beta-lactam antibiotics like penicillins, cephalosporins, and carbapenems. Combining the two classes often kills bacteria faster and more completely than either drug alone. The primary explanation is straightforward: beta-lactams damage the bacterial cell wall, and that damage increases the penetration of aminoglycosides into the cell.14PubMed. Bactericidal synergism between beta-lactams and aminoglycosides: mechanism and possible therapeutic implications In studies with P. aeruginosa, beta-lactam exposure increased the uptake of tobramycin at sub-inhibitory concentrations, producing measurably faster killing over two to four hours.15PubMed Central. Early effects of beta-lactams on aminoglycoside uptake, bactericidal rates, and turbidimetrically measured growth inhibition in Pseudomonas aeruginosa
Interestingly, direct experiments on the outer membrane of P. aeruginosa suggested that the synergy is not mediated by outer membrane disruption per se.16PubMed Central. Penetration of the outer membrane of Pseudomonas aeruginosa by synergistic combinations of beta-lactam and aminoglycoside antibiotics Instead, beta-lactam damage to the inner peptidoglycan layer and cytoplasmic membrane appears to be the gateway that matters. This synergy is exploited routinely in the treatment of serious infections like endocarditis and gram-negative sepsis, where combination therapy can make the difference between clearing an infection and losing ground to it.
Ototoxicity and Genetic Vulnerability
The best-known side effect of aminoglycosides is damage to the inner ear, which can cause irreversible hearing loss or vestibular dysfunction (problems with balance). The drugs accumulate in the sensory hair cells of the cochlea, where they trigger cell death through mechanisms that overlap with their antibacterial action, namely disruption of mitochondrial function and generation of reactive oxygen species. This toxicity is dose-related and more likely with prolonged courses, but it can occasionally appear after short treatment periods.
Some people are genetically predisposed to aminoglycoside-induced hearing loss. Specific mutations in the mitochondrial 12S rRNA gene, particularly m.1555A>G and m.1494C>T, make human mitochondrial ribosomes structurally resemble bacterial ribosomes more closely. This enables stronger aminoglycoside binding inside the patient’s own cells.17PubMed Central. Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity For individuals carrying these mutations, even a single dose can trigger severe or profound sensorineural hearing loss.18Human Genome Variation. Prevalence of the mitochondrial 1555 A>G and 1494 C>T mutations in a community-dwelling population in Japan These mutations are inherited maternally (since mitochondrial DNA comes from the mother) and their prevalence varies across populations. In some settings, pre-treatment genetic screening has been proposed, though it is not yet standard practice everywhere.
Nephrotoxicity and the Role of Megalin
Kidney damage is the other major toxicity concern. Aminoglycosides are filtered by the kidneys and then actively taken back up by the proximal tubular cells, the very cells responsible for reclaiming useful molecules from urine. A receptor protein called megalin, abundantly expressed on the surface of these cells, binds aminoglycosides and pulls them inside through a process called endocytosis.19PubMed. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways Once inside, the drugs accumulate in lysosomes and disrupt normal cellular processes.
Animal studies have demonstrated this link clearly. In rats, aminoglycoside accumulation in the kidney cortex correlated directly with megalin levels, and experimentally reducing megalin expression lowered drug accumulation proportionally.20PubMed. Role of megalin in renal handling of aminoglycosides In mice engineered to lack megalin, gentamicin accumulation in the kidney was markedly reduced.21Journal of Biological Chemistry. Megalin Deficiency Offers Protection from Renal Aminoglycoside Accumulation Megalin-mediated endocytosis is not the only route, however; non-selective cation channels also contribute to aminoglycoside entry into both kidney cells and cochlear hair cells, which complicates the picture for anyone trying to design a selective blocker.19PubMed. Entry of aminoglycosides into renal tubular epithelial cells via endocytosis-dependent and endocytosis-independent pathways
Once-Daily Dosing and the Post-Antibiotic Effect
Aminoglycosides exhibit two pharmacological properties that have reshaped how they are dosed. First, their killing is concentration-dependent: higher peak levels kill bacteria faster and more thoroughly. Second, they produce a post-antibiotic effect, meaning bacterial growth remains suppressed even after drug concentrations fall below the level needed to inhibit growth. Together, these properties mean that giving one large daily dose can be as effective as, or more effective than, splitting the same total amount into multiple smaller doses throughout the day.22PubMed. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides
The toxicity argument for once-daily dosing is equally compelling. Kidney and ear damage correlate with prolonged exposure to moderate drug levels rather than with brief, high peaks. By giving the full dose at once and then allowing a drug-free interval, the kidney’s proximal tubular cells get time to clear accumulated aminoglycoside. Multiple studies and clinical experience have confirmed that once-daily regimens are at least as safe as traditional dosing and possibly less toxic.23Journal of Antimicrobial Chemotherapy. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice This approach has become the standard in most hospitals, though patients with severe kidney impairment or certain other conditions may still require adjusted schedules with drug-level monitoring.
Plazomicin and Next-Generation Design
Drug designers have not given up on the aminoglycoside scaffold. Plazomicin, derived synthetically from sisomicin, was engineered specifically to dodge the most common modifying enzymes. By adding chemical substituents at positions that block the enzymes’ attachment points, plazomicin retains activity against bacteria carrying any of the clinically relevant aminoglycoside-modifying enzymes.24PubMed. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin It has activity against both gram-negative and gram-positive pathogens, including many multidrug-resistant strains. However, plazomicin is still vulnerable to 16S rRNA methyltransferases, since those enzymes modify the ribosomal target rather than the drug. This represents a hard ceiling for any aminoglycoside that binds the same site, no matter how cleverly the molecule’s periphery is modified.
Readthrough Therapy for Genetic Diseases
One of the more surprising chapters in aminoglycoside pharmacology has nothing to do with infection. In eukaryotic cells, some aminoglycosides can cause the ribosome to read through premature stop codons, mutations that prematurely halt protein production and underlie many genetic diseases. If the ribosome can be coaxed past a premature stop, it produces a full-length or near-full-length protein that may be at least partially functional.25PubMed Central. Reducing the Toxicity of Designer Aminoglycosides as Nonsense Mutation Readthrough Agents for Therapeutic Targets
Cystic fibrosis is one of the diseases where this approach has received the most attention, since roughly ten percent of cystic fibrosis cases are caused by nonsense mutations in the CFTR gene. Gentamicin and designer aminoglycoside derivatives have been tested for their ability to restore some CFTR protein production.26PubMed Central. Pharmacological approaches for targeting cystic fibrosis nonsense mutations The challenge is that the concentrations needed for effective readthrough overlap with those that cause kidney and ear toxicity. Researchers are working on modified aminoglycoside structures that retain the readthrough-promoting ability while reducing toxicity, essentially trying to amplify the eukaryotic ribosome interaction that antibiotic designers have spent decades trying to minimize. Duchenne muscular dystrophy, Rett syndrome, and several other genetic conditions caused by premature stop codons are also under investigation as potential targets for this approach.
Why the Structural Chemistry Matters Clinically
Aminoglycosides share a common architecture: a central aminocyclitol ring (most often 2-deoxystreptamine) linked to amino sugars through glycosidic bonds. The specific sugars attached and their positions determine which modifying enzymes can act on a given drug, which ribosomal contacts the drug makes, and therefore which bacteria it can kill. Gentamicin, tobramycin, and amikacin, the three most used aminoglycosides for systemic infections, differ from each other primarily in these sugar substitutions. Amikacin, for example, carries a bulky side chain at position 1 that blocks several common modifying enzymes, which is why it often retains activity when gentamicin and tobramycin have been rendered useless by resistance. Plazomicin extends this principle further with additional protective substituents.
The positive charges scattered across the molecule, carried by amino groups on the sugar rings, are essential for both the drug’s activity and its toxicity. These charges drive electrostatic attraction to the negatively charged bacterial rRNA, to the negatively charged lipopolysaccharide of the gram-negative outer membrane, and unfortunately to the negatively charged phospholipids and receptors in human kidney cells and cochlear hair cells. Any structural modification that reduces positive charge to limit toxicity risks simultaneously weakening antibacterial potency. This fundamental trade-off is the central design constraint for every new aminoglycoside in development, whether intended for infection or for readthrough therapy in genetic disease.